X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA PANACEA BIOTECH PLETHICO PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x -1.1 170.0 - View Chart
P/BV x 0.0 3.8 0.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
PANACEA BIOTECH
Mar-14
PLETHICO PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs395149 265.6%   
Low Rs3182 38.0%   
Sales per share (Unadj.) Rs604.484.1 718.3%  
Earnings per share (Unadj.) Rs32.5-18.3 -177.4%  
Cash flow per share (Unadj.) Rs51.3-6.7 -766.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.683.7 565.7%  
Shares outstanding (eoy) m34.0861.25 55.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.4 25.7%   
Avg P/E ratio x6.6-6.3 -104.0%  
P/CF ratio (eoy) x4.2-17.2 -24.1%  
Price / Book Value ratio x0.51.4 32.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2627,074 102.7%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m1,5961,449 110.1%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m20,5985,154 399.7%  
Other income Rs m386100 387.1%   
Total revenues Rs m20,9845,254 399.4%   
Gross profit Rs m2,818-766 -367.7%  
Depreciation Rs m642711 90.3%   
Interest Rs m1,5931,503 106.0%   
Profit before tax Rs m969-2,881 -33.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m-13817 -823.7%   
Profit after tax Rs m1,107-1,121 -98.7%  
Gross profit margin %13.7-14.9 -92.0%  
Effective tax rate %-14.3-0.6 2,449.8%   
Net profit margin %5.4-21.8 -24.7%  
BALANCE SHEET DATA
Current assets Rs m18,8773,810 495.4%   
Current liabilities Rs m11,8968,365 142.2%   
Net working cap to sales %33.9-88.4 -38.3%  
Current ratio x1.60.5 348.4%  
Inventory Days Days36156 23.1%  
Debtors Days Days19867 294.2%  
Net fixed assets Rs m9,86114,480 68.1%   
Share capital Rs m34161 555.8%   
"Free" reserves Rs m12,331903 1,365.4%   
Net worth Rs m16,1395,127 314.8%   
Long term debt Rs m4,7065,832 80.7%   
Total assets Rs m33,14619,433 170.6%  
Interest coverage x1.6-0.9 -175.4%   
Debt to equity ratio x0.31.1 25.6%  
Sales to assets ratio x0.60.3 234.3%   
Return on assets %8.12.0 414.7%  
Return on equity %6.9-21.9 -31.4%  
Return on capital %12.33.6 338.0%  
Exports to sales %21.424.5 87.2%   
Imports to sales %15.210.2 149.5%   
Exports (fob) Rs m4,4021,264 348.3%   
Imports (cif) Rs m3,136525 597.6%   
Fx inflow Rs m4,4021,539 286.0%   
Fx outflow Rs m3,184942 338.0%   
Net fx Rs m1,219597 204.0%   
CASH FLOW
From Operations Rs m2,437599 406.8%  
From Investments Rs m-6,265-438 1,430.6%  
From Financial Activity Rs m2,490-303 -822.9%  
Net Cashflow Rs m-1,337-141 946.3%  

Share Holding

Indian Promoters % 82.7 74.5 111.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 0.6 716.7%  
FIIs % 5.5 1.3 423.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 23.6 31.8%  
Shareholders   10,665 10,259 104.0%  
Pledged promoter(s) holding % 85.7 35.1 244.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   NOVARTIS  TORRENT PHARMA  DISHMAN PHARMA  CIPLA  ABBOTT INDIA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS